<DOC>
	<DOCNO>NCT01066494</DOCNO>
	<brief_summary>A phase IIa study evaluate pharmacokinetic efficacy amonafide L-malate ( AS1413 ) combination cytarabine treat patient acute myeloid leukemia ( AML )</brief_summary>
	<brief_title>A Pharmacokinetic Efficacy Study Amonafide L-malate ( AS1413 ) Combination With Cytarabine Patients With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Amonafide</mesh_term>
	<criteria>1 . Willing able provide write informed consent 2 . In opinion Investigator able comply study assessment followup 3 . New diagnosis AML ( i.e . &gt; 20 % blast ) define World Health Organization ( WHO ) classification ( Vardiman 2009 ) relapse refractory AML define persistence recurrence &gt; 5 % blast bone marrow peripheral blood follow treatment . 4 . ECOG Performance status ≤ 2 5 . Age &gt; 18 year ≤ 70 year 6 . Adequate hepatic function evidence follow laboratory test : 1 . Total serum bilirubin ≤ 1.5 x ULN direct ( conjugate ) bilirubin ≤ 1.5 ULN unless attributable suspect hepatic involvement AML 2 . Serum AST ALT ≤ 1.5 x ULN unless attributable suspect hepatic involvement AML 7 . Adequate renal function evidence serum creatinine ≤ 1.5 x ULN 8 . Women childbearing potential must negative serum pregnancy test . A woman childbearing potential define one biologically capable become pregnant . This include woman use contraceptive whose sexual partner either sterile use contraceptive 9 . Left Ventricular Ejection Fraction ( LVEF ) &gt; 50 % , determine multiplegated acquisition scan ( MUGA ) echocardiogram ( ECHO ) within 28 day prior administration 1st dose remission induction chemotherapy 1 . Unwilling accept require per protocol blood urine sample collection 2 . An initial diagnosis acute promyelocytic leukemia define French AmericanBritish criterion ( Bennett 1976 ) ( otherwise know FAB M3 ) 3 . Clinically active CNS leukemia 4 . History clinically significant allergic reaction attribute compound similar chemical biological composition amonafide cytarabine 5 . Pregnant breast feed 6 . Known HIV positive 7 . Known active hepatitis B C , active liver disease 8 . Evidence pulmonary infection . Patients evidence pulmonary infection screen chest xray chest compute tomography ( CT ) prior start remission induction therapy confirm absence presence pulmonary infection . 9 . Any major surgery radiation therapy within 30 day prior study entry 10 . Previously receive treatment amonafide 11 . Treatment investigational agent reason within 30 day prior study entry 12 . Prior remission induction therapy AML within 30 day start amonafide therapy 13 . Persistent nonhematologic toxicity ( alopecia ) great Grade 2 prior therapy MDS AML 14 . Serious concomitant illness ( example , unstable angina myocardial infarction stroke within 3 month prior study entry , congestive heart</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>AML</keyword>
	<keyword>Pgp</keyword>
	<keyword>MDR</keyword>
	<keyword>sAML</keyword>
	<keyword>AS1413</keyword>
	<keyword>Amonafide</keyword>
</DOC>